文献速递心脑血管急症复苏、休克与脓毒症重症综合管理与镇静镇痛

体外膜氧合支持危及生命的药物难治性电风暴

Extracorporeal Membrane Oxygenation to Support Life-Threatening Drug-Refractory Electrical Storm.
PubMed 文献 · Crit Care Med · 2020-01-01
一句话结论药物难治性电风暴患者接受静脉-动脉体外膜氧合支持后,42%在ICU入住后6个月存活,年龄小于50岁及室速/室颤与短阵窦律交替者生存更好。

这项回顾性多中心研究纳入了法国两家三级医疗中心8年间83例接受静脉-动脉体外膜氧合支持的药物难治性电风暴成人患者(中位年龄55岁)。59%为急性缺血性心肌病,66%在体外膜氧合前接受过心肺复苏。中位支持3天后,45%成功脱机,42%在ICU入住后6个月存活。多变量分析显示室速/室颤与短阵窦律交替(OR 0.18,95%CI 0.06-0.52)和年龄小于50岁(OR 0.32,95%CI 0.18-0.89)是与6个月生存独立相关的保护因素。

要点

  • 83例药物难治性电风暴成人接受静脉-动脉体外膜氧合支持,42%在ICU入住后6个月存活。
  • 室速/室颤与短阵窦律交替者6个月生存的OR为0.18(95%CI 0.06-0.52,p=0.002),年龄小于50岁者OR为0.32(95%CI 0.18-0.89,p=0.002)。
  • 66%患者在体外膜氧合前接受过心肺复苏,18%在体外膜氧合置管期间接受心肺复苏。
  • 中位体外膜氧合支持3天(1-13天)后,45%成功脱机。
  • 15%的患者在体外膜氧合支持下安全接受了导管消融。

适用人群与场景

  • 成人药物难治性电风暴患者,接受静脉-动脉体外膜氧合支持(连续纳入83例,中位年龄55岁,四分位距48-63岁)。
  • 59%为急性缺血性心肌病,66%在体外膜氧合前接受过心肺复苏,18%在体外膜氧合置管期间接受心肺复苏。

诊断标准与关键阈值

  • 药物难治性电风暴:尽管快速实施抗心律失常治疗、镇静及控制触发事件,仍出现治疗难治性电风暴,且血流动力学不稳定妨碍急诊导管消融。
  • 60%患者为室速和/或室颤与短阵窦律交替,40%为难治性室速和/或室颤。

处置流程与药物剂量

  • 静脉-动脉体外膜氧合用于快速恢复血流动力学和组织灌注、降低心肌氧耗,直至抗心律失常药物达到足够水平以安全实施导管消融。
  • 15%患者在静脉-动脉体外膜氧合支持下安全接受了导管消融。
  • 中位体外膜氧合支持3天(1-13天)后,45%成功脱机。

研究设计与关键结果

  • 回顾性多中心研究,纳入法国两家三级医疗中心8年间83例连续成人药物难治性电风暴患者,均接受静脉-动脉体外膜氧合支持。
  • 中位体外膜氧合支持3天(1-13天)后,37例(45%)成功脱机,42%在ICU入住后6个月存活。
  • 多变量分析显示,室速和/或室颤与短阵窦律交替(OR 0.18;95%CI 0.06-0.52;p=0.002)和年龄小于50岁(OR 0.32;95%CI 0.18-0.89;p=0.002)是与6个月生存独立相关的保护因素,与电风暴基础病因无关。

证据类型、等级与局限

  • 证据类型:回顾性多中心研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 对于药物难治性电风暴且血流动力学不稳定妨碍急诊导管消融的成人患者,静脉-动脉体外膜氧合可支持血流动力学直至抗心律失常药物达到足够水平以安全实施导管消融。
  • 年龄小于50岁及室速/室颤与短阵窦律交替的患者接受静脉-动脉体外膜氧合支持后6个月生存率更高。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVES: Despite rapid implementation of anti-arrhythmic treatment and sedation and controlling the triggering event, rare patients develop treatment-refractory electrical storm and their hemodynamic instability prevents emergency catheter ablation. In that context, venoarterial extracorporeal membrane oxygenation could rapidly restore hemodynamics and tissue perfusion and reduce myocardial oxygen consumption, until adequate anti-arrhythmic drug levels are reached to safely perform catheter ablation.

DESIGN: Retrospective, multicenter study over an 8-year period.

SETTING: Two French tertiary care centers.

PATIENTS: Eighty-three consecutive adults with venoarterial extracorporeal membrane oxygenation-supported treatment-refractory electrical storm (median [interquartile range] age, 55 yr [48-63 yr]).

MEASUREMENTS AND MAIN RESULTS: Fifty-nine percent of these patients had acute ischemic cardiomyopathy and 66% underwent cardiopulmonary resuscitation prior to venoarterial extracorporeal membrane oxygenation initiation, with 18% cannulated during it. Fifty patients (60%) had ventricular tachycardia and/or ventricular fibrillation alternating with short periods of sinus rhythm and 33 (40%) had refractory ventricular tachycardia and/or ventricular fibrillation. Twelve patients (15%) underwent safe catheter ablation under venoarterial extracorporeal membrane oxygenation. After a median of 3 days (1-13 d) on extracorporeal membrane oxygenation support, 37 patients (45%) were successfully weaned off and 42% were alive 6 months post-ICU admission. Multivariable analysis retained ventricular tachycardia and/or ventricular fibrillation episodes alternating with short periods of sinus rhythm (odds ratio, 0.18; 95% CI, 0.06-0.52; p = 0.002) and age less than 50 years (odds ratio, 0.32; 95% CI, 0.18-0.89; p = 0.002) as being independent protective factors with 6-month survival, regardless of the underlying electrical storm cause.

CONCLUSIONS: Among venoarterial extracorporeal membrane oxygenation-supported drug-refractory electrical storm patients, 42% survived 6 months post-ICU admission. Ventricular tachycardia and/or ventricular fibrillation episodes alternating with short periods of sinus rhythm and age less than 50 years were independently associated with better survival.

来源:Crit Care Med,查看原文。版权归原作者所有。

参考来源

  1. Baudry G, Sonneville R, Waintraub X, et al. Extracorporeal Membrane Oxygenation to Support Life-Threatening Drug-Refractory Electrical Storm. Crit Care Med. 2020. PMID: 32796185. doi:10.1097/CCM.0000000000004490

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。